Regional pretracheal lymphotropic antibiotic therapy for pulmonary complications of COVID-19

Abstract

Purpose of the study: to study the pharmacokinetics of gentamicin in pretracheal lymphotropic antibiotic therapy and regional stimulation of interstitial lung lymphatic drainage.Material and methods. Experimental studies consisted of a single administration of gentamicin to 50 mongrel white rats, both sexes, body mass 370–400 g, at a dose of 30 mg/kg: lymphotropically pretracheal, using lidase as a lymphatic drainage stimulator, and intramuscularly, followed by thoracotomy, undertaken to remove the chest cavity organs, paratracheal lymph nodes, and femoral vein puncture, for blood sampling. A dynamic determination of the concentration of gentamicin in the blood and extracted tissues was performed. In 10 mongrel rats, both sexes, body mass 440–470 g, the rate of lymphatic drainage of the lungs was studied using the Kety radionuclide method using Albumin I-131, with pretracheal administration of a non-concentrated lidase solution.Results. Data analysis pharmacokinetics and radionuclide study of the lymph showed that the method of lymphotropic pretracheal the introduction of antibiotics and regional lymphostimulation, may have advantages over traditional methods of drug administration in the treatment of pneumonitis (interstitiopathy) at COVID-19, due to the higher and prolonged content in the tissues and the lymphatic channel of the bronchopulmonary system (p < 0,05) – the place of greatest congestion and infection, as well as lymphatic drainage of the lungs.Conclusion. The method of lymphotropic pretracheal administration of antibiotics and regional lymphostimulation may have advantages over traditional methods of drug administration in the treatment of pulmonary complications in COVID-19.